ArticleNature communications2019
Landscape of transcriptomic interactions between breast cancer and its microenvironment.
Article in Nature communications, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- A guide to transcriptomic deconvolution in cancer.Nature reviews. Cancer · 2026Review
- iSubGen generates integrative disease subtypes by pairwise similarity assessment.Cell reports methods · 2024Article
- Longitudinal molecular profiling elucidates immunometabolism dynamics in breast cancer.Nature communications · 2024Article
- Multiomics insights on the onset, progression, and metastatic evolution of breast cancer.Frontiers in oncology · 2023Review
- [CD40LG is a novel immune- and stroma-related prognostic biomarker in the tumor microenvironment of invasive breast cancer].Nan fang yi ke da xue xue bao = Journal of Southern Medical University · 2022Article
- Deconvolving Clinically Relevant Cellular Immune Cross-talk from Bulk Gene Expression Using CODEFACS and LIRICS Stratifies Patients with Melanoma to Anti-PD-1 Therapy.Cancer discovery · 2022Article
- Functional annotation of breast cancer risk loci: current progress and future directions.British journal of cancer · 2022Review
- Article
- The Significance of Tumor Microenvironment Score for Breast Cancer Patients.BioMed research international · 2022Article
- Proteomic discovery of non-invasive biomarkers of localized prostate cancer using mass spectrometry.Nature reviews. Urology · 2021Review
- Article
- The temporal mutational and immune tumour microenvironment remodelling of HER2-negative primary breast cancers.NPJ breast cancer · 2021Article
- Hybrid Graphene-Gold Nanoparticle-based Nucleic Acid Conjugates for Cancer-Specific Multimodal Imaging and Combined Therapeutics.Advanced functional materials · 2021Article
- A Novel Immune and Stroma Related Prognostic Marker for Invasive Breast Cancer in Tumor Microenvironment: A TCGA Based Study.Frontiers in endocrinology · 2021Article
- A High Epigenetic Risk Score Shapes the Non-Inflamed Tumor Microenvironment in Breast Cancer.Frontiers in molecular biosciences · 2021Article
- CD2 Is a Novel Immune-Related Prognostic Biomarker of Invasive Breast Carcinoma That Modulates the Tumor Microenvironment.Frontiers in immunology · 2021Article
- Integrative pathway enrichment analysis of multivariate omics data.Nature communications · 2020Article
- Systematic Assessment of Tumor Purity and Its Clinical Implications.JCO precision oncology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Solid tumours comprise mixtures of tumour cells (TCs) and tumour-adjacent cells (TACs), and the intricate interconnections between these diverse populations shape the tumour's microenvironment. Despite this complexity, clinical genomic profiling is typically performed from bulk samples, without distinguishing TCs from TACs. To better understand TC-TAC interactions, we computationally distinguish their transcriptomes in 1780 primary breast tumours. We show that TC and TAC mRNA abundances are divergently associated with clinical phenotypes, including tumour subtypes and patient survival. These differences reflect distinct responses of TCs and TACs to specific somatic driver mutations, particularly TP53. These data further elucidate how the molecular interplay between breast tumours and their microenvironment drives aggressive tumour phenotypes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.